Ongoing study
Official Study Title
THE ROLE OF PANCREATIC STONE PROTEIN (PSP) AND PSP-GUIDED EARLY MEROPENEM TREATMENT TO MITIGATE SEPSIS RISK AT THE EMERGENCY DEPARTMENT
Brief Description
The goal of this clinical trial is to demonstrate the clinical benefit of early intervention with meropenem in adult patients of both sexes with suspected infection and risk of sepsis. The primary objective is to evaluate the clinical benefit of a protein called Pancreatic Stone Protein (PSP), which, if elevated, indicates that patient may be at increased risk of developing sepsis. The secondary objectives are to investigate the impact of early antibiotic treatment with meropenem on progression to sepsis, survival and mortality. Researchers will compare meropenem to a placebo (a look-alike substance that contains no drug).
Details
Status: Recruiting
Study Type: Interventional (Clinical Trial)
Study phase: III
Study sites: 10 sites in Greece
Target of enrolment: 398 participants
ClinicalTrials.gov Identifier: NCT07813767
CTIS number: 2025-525006-37-00
Study Start: September 2026
Keywords: Pancreatic Stone Protein (PSP)